Elixiron Immunotherapeutics, Inc. (hereinafter referred to as " Elixiron ") is dedicated to developing precision-targeted immunotherapy drugs designed based on precise immunological approaches to address specific pathogenic immune mechanisms. Founded in 2017, Elixiron 's core innovation stems from the decades-long translational medical research achievements of its three founders in the fields of neuroinflammation, autoimmune diseases, and oncology. The company was recently honored with the 2024 Outstanding Biotechnology Industry Award.
Dr. Hung-Kai Chen, Chairman and Co-Founder, brings extensive experience in clinical medicine, academic research, and industry development. Under his leadership, the innovative drug EI-1071, a highly selective, brain-penetrant small-molecule targeted immunosuppressant, is currently in Phase II clinical trials for Alzheimer's disease. This invention received the 2020 National Invention and Creation Gold Award and has been widely recognized by international scholars and experts. It also earned support from the Alzheimer's Association in 2020 and 2022, accelerating its clinical development for neuroinflammation and offering new hope for the treatment of Alzheimer's patients.
In the field of autoimmune diseases, co-founder Professor Cheng-Lun Ku leads the development of the immune antibody drug EI-001. Several research findings, including publications in top-tier journals such as Nature Medicine, highlight the novel applications of EI-001 in treating vitiligo. The drug has now progressed to Phase I clinical trials in humans.
 |
New Clinical IndicationsExpand new indications through clinical translational medicine based on confirmed pharmacological effects.
|
|
Innovative Technology PlatformsBuilding advanced platform technologies to accelerate drug development
|
||
Novel Therapeutic TargetsInternational industry-university collaboration discovers new targets for disease treatment
|
New Clinical Indications |
|
|
In the first phase, through clinical immunology research, Elixiron collects and analyzes extensive clinical data to investigate pathogenic immune mechanisms and identify the optimal combination of drugs and indications. This approach has led to the proposal of novel treatment strategies using precision-targeted immunotherapy for Alzheimer's disease and vitiligo. These efforts have also earned Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis and hemophagocytic lymphohistiocytosis (HLH). |
|
Innovative Technology Platforms |
|
|
In the second phase, Elixiron has developed proprietary platforms, including single B-cell cloning technology, an AI-designed antibody sequence library, T-Action Technology, and a nucleic acid drug development platform. These cutting-edge technologies have significantly accelerated the development of multiple novel drug candidates. |
|
Novel Therapeutic Targets |
|
|
In the third phase, under the leadership of co-founder Professor Mu-Hua Yang, the tumor microenvironment of head and neck cancer has been thoroughly analyzed, revealing key mechanisms of immune suppression. This research has enabled the identification of novel therapeutic targets and the development of innovative targeted immunotherapies. Among them, the dual-functional antibody drug EI-003 was published in the journal Cell Reports Medicine in 2023. |
Elixiron Immunotherapeutics, Inc. (hereinafter referred to as " Elixiron ") is dedicated to developing precision-targeted immunotherapy drugs designed based on precise immunological approaches to address specific pathogenic immune mechanisms. Founded in 2017, Elixiron 's core innovation stems from the decades-long translational medical research achievements of its three founders in the fields of neuroinflammation, autoimmune diseases, and oncology. The company was recently honored with the 2024 Outstanding Biotechnology Industry Award.
Dr. Hung-Kai Chen, Chairman and Co-Founder, brings extensive experience in clinical medicine, academic research, and industry development. Under his leadership, the innovative drug EI-1071, a highly selective, brain-penetrant small-molecule targeted immunosuppressant, is currently in Phase II clinical trials for Alzheimer's disease. This invention received the 2020 National Invention and Creation Gold Award and has been widely recognized by international scholars and experts. It also earned support from the Alzheimer's Association in 2020 and 2022, accelerating its clinical development for neuroinflammation and offering new hope for the treatment of Alzheimer's patients.
In the field of autoimmune diseases, co-founder Professor Cheng-Lun Ku leads the development of the immune antibody drug EI-001. Several research findings, including publications in top-tier journals such as Nature Medicine, highlight the novel applications of EI-001 in treating vitiligo. The drug has now progressed to Phase I clinical trials in humans.
 |
New Clinical Indications |
|
Expand new indications through clinical translational medicine based on confirmed pharmacological effects.
|
 |
Innovative Technology Platforms |
|
Building advanced platform technologies to accelerate drug development
|
 |
Novel Therapeutic Targets |
|
International industry-university collaboration discovers new targets for disease treatment
|
Elixiron Immunotherapeutics’s drug development strategy, known as the “Innovation Trilogy,” comprises three pillars: new clinical indications, innovative technology platforms, and novel therapeutic targets.
1. New Clinical Indications |
|
In the first phase, through clinical immunology research, Elixiron collects and analyzes extensive clinical data to investigate pathogenic immune mechanisms and identify the optimal combination of drugs and indications. This approach has led to the proposal of novel treatment strategies using precision-targeted immunotherapy for Alzheimer's disease and vitiligo. These efforts have also earned Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF) and hemophagocytic lymphohistiocytosis (HLH). |
2. Innovative Technology Platforms |
|
In the second phase, Elixiron has developed proprietary platforms, including single B-cell cloning technology, an AI-designed antibody sequence library, T-Action Technology, and a mRNA drug development platform. These cutting-edge technologies have significantly accelerated the development of multiple novel drug candidates. |
3. Novel Therapeutic Targets |
|
In the third phase, under the leadership of co-founder Professor Mu-Hua Yang, the tumor microenvironment of head and neck cancer has been thoroughly analyzed, revealing key mechanisms of immune suppression. This research has enabled the identification of novel therapeutic targets and the development of innovative targeted immunotherapies. Among them, the dual-functional antibody drug EI-003 was published in the journal Cell Reports Medicine in 2023. |
